BioSpace News Archive

Aura Biosciences Inc. today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences.

Confluent Medical has experienced significant improvements to its end-to-end supply chain with Kinaxis.

Moderna, Inc. (NASDAQ:MRNA) today will unveil its comprehensive AI and digital strategy at its second Digital Investor Event. Building off its Manufacturing and Digital Day hosted in March 2020, the Company will showcase how AI continues to transform the organization and enhance its value creation.

BridgeBio Pharma, Inc. today announced that on November 07, 2023, the compensation committee of BridgeBio’s board of directors granted thirty-three new employees restricted stock units for an aggregate of 183,533 shares of the Company’s common stock.

HCW Biologics Inc.announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

Profound Medical Corp. today announced that management will present an update on the Company’s business at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. Eastern Time in NYC.

K36 Therapeutics has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.

Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, announced that company management will present at two upcoming investor conferences..

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent corporate developments.